T 4 -binding protein composition and the T 4 or FT
in maternal serum. The binding capacity is determined ontogenically, is independent of maternal thyroid status, and is far in excess of the T 4 in fetal fluids. Thus, the availability of FT 4 for embryonic and fetal tissues would decrease in hypothyroxinemic women, even if they were euthyroid. A decrease in the availability of FT 4 , a major precursor of intracellular nuclear receptor-bound T 3 , may result in adverse effects on the timely sequence of developmental events in the human fetus. These findings ought to influence our present approach to maternal hypothyroxinemia in early pregnancy regardless of whether TSH is increased or whether overt or subclinical hypothyroidism is detected. T HYROID HORMONES are essential for fetal brain development, but the timing of onset of the different events that are thyroid hormone dependent has not yet been clearly defined, in particular for the first trimester of human development (1) . This uncertainty persists despite the demonstration that nuclear TR, partially occupied by T 3 , are present in first trimester human fetal brain tissue (2) (3) (4) . This suggests that thyroid hormone-mediated effects may already occur in the early fetus.
It is important to clarify this point. There is increasing evidence from epidemiological and experimental data (5) that first trimester maternal thyroid status is pivotal for the outcome of pregnancy (6) and for the neuropsychomotor development of the child (7, 8) . Efforts to detect and prevent maternal hypothyroxinemia in early pregnancy appear fully justified (5) . Indeed, neurodevelopment defects, including an increased probability of cerebral palsy, may be 150 times more frequent than those resulting from untreated congenital hypothyroidism.
More direct evidence obtained from human fetal fluids is still needed to better understand the maternal-fetal thyroid hormone relationships before the onset of fetal thyroid secretion. Available information up to midgestation is scarce, especially for fetal fluid samples obtained before interruption of maternal to fetal connections. During this period two distinct modes of maternal-fetal nutrient transfer occur sequentially. For most of the first trimester the human fetus is surrounded by two distinct fluid cavities separated from each other by a thin membrane (Fig. 1A ): the inner, or amniotic, cavity contains the fetus, and the outer, or exocoelomic, cavity separates the amniotic cavity from the placenta and contains the secondary yolk sac (9) . The secondary yolk sac is directly connected to the fetal digestive tract and circulation. The investigation of early fetal fluids has demonstrated that the exocoelomic cavity is the site of important molecular exchanges between the mother and the fetus (10 -13) . The coelomic fluid results from an ultrafiltrate of maternal serum with the addition of specific placental and secondary yolk sac bioproducts (10 -12, 14) . The exocoelomic cavity is clearly a physiological liquid extension of the early placenta that may act as a reservoir for nutrients needed by the developing fetus (13) . We previously demonstrated that T 4 (and possibly T 3 ) is indeed present in coelomic fluid (CF) samples as early as 5.6 wk gestation (15) . These preliminary data show that maternal thyroid hormones are potentially available to early fetal tissues, but raise new questions about whether the thyroid hormone concentrations found inside the gestational sac could be biologically relevant for the occupation of nuclear TR in the fetal brain.
The second mode of transfer starts at the end of the first trimester. The secondary yolk sac and two thirds of the placental mass degenerate, and the exocoelomic cavity is progressively obliterated by the growing amniotic cavity containing the fetus (Fig. 1B) . These major anatomical transformations modify considerably the spatial relationships between maternal tissue and developing fetus, and, consequently, the maternal-fetal exchange pathways. From 11-12 wk onward, maternal nutrients, including thyroid hormone, are transferred via the placenta directly into the fetal circulation. Thyroid hormone levels in fetal serum (FS) had only occasionally been measured during the same period (16) . The aim of this study was to further investigate the distribution of thyroid hormones inside the first trimester exocoelomic and amniotic cavities, to determine thyroid hormone concentrations in the second trimester amniotic cavity and fetal circulation, and to quantify the concentrations of the T 4 likely to be available to fetal tissues, namely those of free T 4 (FT 4 ), and interrelationships with maternal circulating iodothyronines.
Materials and Methods

Subjects and samples
We have studied four series of samples. Series A and B consisted of matched samples of CF, amniotic fluid (AF), and maternal serum (MS) at 5.6 -12 wk gestation. Series A corresponds to the 13 women presented in our previous report (15) , all of whom were Caucasian. Series B comprised samples from 20 women collected in a different area of London; 12 were from ethnic minorities (7 black African and 5 Asian). The third series of samples (C) included matched samples of CF, AF, and MS at 7.6 -11.6 wk (n ϭ 15) and of AF, FS, and MS at 11.6 -17.1 wk gestation (n ϭ 28); 9 women were black African, and 4 were Asian. Series D consisted of first trimester CF and AF samples (n ϭ 32) for which MS was not available. These samples were used for necessary verifications of some of the analytical procedures (HPLC; percent FT 4 and percent FT 3 ). All samples were collected before elective surgical termination of pregnancy under general anesthesia. Gestational age was determined from the first day of the last menstrual period and was confirmed by ultrasound measurement of the fetal crown-rump length. Written consent was obtained from each woman after receiving complete information on the procedure. The study included only uncomplicated pregnancies and was approved by University College London Hospitals committee on the ethics of human research.
CF and AF samples were obtained by trans-vaginal puncture under sonographic guidance (10, 12, 13) . The first 0.2 ml of each fluid was discarded to decrease the risk of contamination by maternal blood. Fetal blood samples of 2.0 -5.0 ml were aspirated by ultrasonographically guided intracardiac puncture (13) . The samples were collected in heparinized tubes, centrifuged within 60 min of collection. In all cases, maternal venous blood was obtained during the surgical procedure. FS and MS samples were stored at Ϫ20 C until assayed; CF and AF were stored at Ϫ70 C.
Determination of T 4 , T 3 , and rT 3 in fetal fluids
Aliquots (400 l) from each CF sample were taken to determine T 4 and rT 3 concentrations individually. The rest was used to measure the T 3 concentrations and the percent FT 4 , for which 1-4.5 ml are needed. With AF, 200-l aliquots were sufficient to evaluate the percent FT 4 , but 3-6 ml were needed for the assays of T 4 and T 3 . If necessary, CF or AF samples were pooled according to equivalent gestational age. The iodothyronines were determined using highly sensitive and specific RIAs after extensive extraction and purification with methods previously described in detail (17, 18) 3 were added to each sample as internal tracers for recovery calculations. The samples were extracted with a 2.5-fold volume of ethanol, and the ethanol extracts were further purified on AG 1 ϫ 2 resin columns (Bio-Rad Laboratories, Inc., Richmond, CA), from which the iodothyronines were eluted with 70% acetic acid, pooled, evaporated to dryness, and extensively counted for the calculation of individual recoveries. RIA buffer was then added, and the iodothyronine contents were determined by RIAs in duplicate at two dilutions. The limits of detection are 3.2 fmol T 4 , 1.0 pmol T 3 , and 1.5 pmol rT 3 /tube.
Verification of the presence of thyroid hormones in coelomic fluid by HPLC
CF samples were extracted twice with ethanol-0.5 n HCl (10:0.5, vol/vol). After centrifuging at 2000 rpm for 10 min, the supernatants were mixed and neutralized with 200 l ammonia and passed through Dowex AG 1 ϫ 2 columns as described above. The iodothyronines were eluted with 70% acetic acid and evaporated to dryness. The residue was dissolved in 100 l 0.3 n ammonia and transferred to a Chromspher 5 4 and T 3 were separated with an isocratic gradient using 55% methanol and 45% 0.015 m ammonium acetate, pH 3.5-4, at a rate of 0.6 ml/min. The fractions corresponding to the labeled iodothyronines were evaporated to dryness, and 200 l RIA buffer were added. The RIAs were performed as described above.
Percentages of free T 4 and T 3 in fetal fluids
The percent FT 4 was determined in undiluted samples of CF and AF, with slight modifications to the method described by Mendel et al. (19) . A 5-l aliquot of high specific activity [
125 I]T 4 (ϳ350,000 cpm for CF and 70,000 cpm for AF) was added to 195 l sample and incubated at room temperature for 1 h. A 180-l aliquot of each labeled CF or AF sample was ultrafiltered using Microcon 10 microconcentrators (Amicon Division, W.R. Grace Co., Beverly, MA) and centrifuged for 30 min at 3000 rpm. A measured volume of each ultrafiltrate and of the initial tracer was added to 0.2 ml bovine serum and precipitated with 2.5 ml 10% trichloroacetic acid; the pellet was counted after being washed twice with the trichloroacetic acid solution. The radioactivity in the pellet was calculated as a percentage of the tracer initially added. Each sample was processed in duplicate. The percent FT 4 and the total T 4 determined by RIA were used to calculate the concentrations of FT 4 .
The percent FT 3 was determined in some undiluted CF samples using the same procedure as that used to calculate the percent FT 4 , but only approximately 100,000 cpm high specific activity [
125 I]T 3 were added. 4 (ϳ3000 Ci/g) were synthesized by our laboratory as previously described (17) .
Drugs and reagents
Other assays
Hemoglobin content was measured in 10-l aliquots of CF and AF (20) . To assess the amounts of T 4 and T 3 from maternal blood that might have contaminated CF or AF samples, we used the T 4 and T 3 concentrations in MS and assumed a value of 140 g/liter for hemoglobin and a 50% hematocrit.
Total T 4 in MS was measured by RIA, and free T 4 in MS and FS was measured by a two-step RIA method (Gammacoat kits provided by Clinical Assays, INCSTAR, Stillwater, MN), T 3 was determined using the Amerlex RIA (Amersham Pharmacia Biotech, Little Chalfont, UK), rT 3 was determined using an RIA kit (Tickland, Liege, Belgium), FT 3 in MS was determined with the Dynotest FT 3 kit from Brahms Diagnostica GmbH (Berlin, Germany), TSH in MS and FS was determined by immunoradiometric assay, and T 4 -binding globulin (TBG) was determined by RIA, with commercial kits (Behring, Marburg, Germany). The coefficients of variation were less than 10 for T 3 , T 4 , and FT 4 ; less than 5% for TSH; and less than 10% for TBG and rT 3 .
Transthyretin (TTR) concentrations in MS and CF were determined by immunonephelometry, using antihuman transthyretin Ab (Behring) on the Behring nephelometer analyzer. The concentrations of albumin, ␣ 1 -, ␣ 2 -, ␤-, and ␥-globulins in CF were quantified by densitometry after electrophoresis (14) with a 5% coefficient of variation.
Intact hCG was measured using a solid phase RIA based on the principle of the sandwich assay (RIA-gnost hCG, Behring). The sensitivity and intraassay coefficient of variations of this test were 1 IU/liter and less than 5%, respectively.
To test likely interferences in the TSH RIA when samples contained very high concentrations of hCG, we obtained purified hCG␤ (provided by Dr. A. F. Parlow from National Hormone and Pituitary Programs, NIDDK, NIH). Native hCG obtained from pregnant human urine was supplied by Sigma (St. Louis, MO).
Statistical analysis
The data were analyzed SPSS 6.1 (SPSS, Inc., Chicago, IL). All values are expressed as the mean Ϯ se. One-way ANOVA, followed by the least significant difference post-hoc test, were used to compare mean values of different series of data. Partial correlation analysis was performed, and Pearson's correlations coefficients were calculated; P Ͻ 0.05 was considered statistically significant. Most of the variables measured in the present study were positively correlated with gestational age, and partial correlation analyses disclosed that most of the correlations between variables were spurious, as only a few persisted after correcting for gestational age. Unless stated otherwise, only those correlations that were independent of gestational age are considered here. Table 1 summarizes the results obtained in the MS from series A-C. Series C was further divided into groups C 1 (first trimester) and C 2 (second trimester). First trimester levels of T 4 and TSH were the same in all groups, but T 4 was higher in second trimester samples. FT 4 levels were lower in groups B, C1, and C2 compared with A, whereas T 3 levels were higher. The T 3 /T 4 molar ratio was increased in all groups compared with group A. FT 3 (not shown in Table 1 ) was only measured in series C and increased between the first and second trimester MS from 6.32 Ϯ 0.25 to 7.49 Ϯ 0.23 pmol/ liter (P ϭ 0.002), as did the FT 3 /FT 4 molar ratio, from 0.305 Ϯ 0.017 to 0.427 Ϯ 0.016 (P Ͻ 0.001).
Results
Gestational age and maternal thyroid function
Anti-TPO Ab titers above 200 U/ml were found in 6 of the 60 women where these were measured. Slightly elevated TSH levels (Ͼ6 mU/liter) were found in 4 of the 72 women, with very high anti-TPO Ab titers present in 3 of these 4 women. Circulating T 4 , FT 4 , and T 3 were within the normal range for pregnancy in all 76 study women, except 1 with normal TSH levels but T 4 and FT 4 values near the lower limits for the normal population. All these features are consistent with other reports for normal pregnant European and North American women (21) (22) (23) . No fetal samples were excluded on the basis of maternal thyroid status. The iodothyronine levels and ratios suggest that women in groups B and C were mildly iodine deficient (23, 24) . The increase in plasma T 3 /T 4 ratios with gestation also suggests that the iodine intake of these women was not adequate for their increasing pregnancy requirements. Our results are therefore relevant to pregnant women with mild to moderate iodine deficiency, but without primary thyroid disease.
Verification by HPLC of the presence of thyroid hormones in CF
The peaks of both iodothyronines, obtained by RIA, coincided with the peaks of in vitro added labeled T 3 and T 4 ( Fig. 2) , thus confirming the specificity of results obtained by RIA in the purified CF. Table 2 shows the comparison between T 4 , FT 4 , T 3 , and rT 3 concentrations in CF and AF samples from all series (A-D). No significant differences were found between the concentrations of T 4 or T 3 in first trimester CF from different series; rT 3 was higher in the C series and was 2-to 4-fold higher than T 4 in all series. The T 3 levels are still tentative estimates, as larger volumes of a greater number of CF samples are needed for a more reliable assessment. Nevertheless, T 3 levels appeared to be 30 -50 times lower than T 4 and 100 times lower than rT 3 . T 4 , T 3 , and rT 3 were also found in those AF samples in which the volume was sufficient to attempt their determination. The total concentrations of all three iodothyronines were lower in AF than in age-paired first trimester CF samples, but FT 4 levels were higher. Both T 4 and rT 3 concentrations were higher in the second trimester AF samples. AF volumes required for the determination of T 3 were large, excluding determinations in series C and D.
Comparison of thyroid hormones concentration in fetal fluids
The contamination of CF and AF with maternal blood was very slight, if any, and it barely affected the T 4 values for the fetal fluids. It accounted for 4% of the total CF T 4 in one of the very few hemoglobin-positive samples and even less in the others.
rT 3 levels correlated with T 4 in both CF and AF (P Ͻ 0.001). No correlations were found in CF or AF between T 3 and either T 4 or rT 3 , but the available T 3 data were limited (see above). Correlations of the different variables between the two cavities were not found.
The percent FT 4 and FT 4 concentrations were measured in CF and AF from series B-D. Initial results obtained with samples from series B indicated that the CF and AF percent FT 4 values were much higher than those in MS. Despite the more than 150-fold difference in total T 4 between CF, or AF, and MS, the concentrations of FT 4 were of the same order of magnitude and should, therefore, be potentially measurable with FT 4 kits used for human serum. We repeatedly attempted this with several commercial kits [Dynotest FT 4 , Brahms Diagnostica GmbH, Amerlex MAB FT 4 , Ortho-Clinical Diagnostics (Amersham Pharmacia Biotech), Clinical Assays Gammacoat two-step FT 4 , INCSTAR Corp. (Stillwater, MN), and FT 4 by equilibrium dialysis (Nichols Institute Diagnostics, San Juan Capistrano, CA)] and concluded they cannot be used to measure FT 4 in CF and AF, because the standards in these kits mimic the protein content of human sera, which is markedly different from that of CF and AF. Results, including those obtained with the dialysis kit, were not only unreliable when using CF or AF, but also when using ultrafiltrates of MS.
We reverted to the ultrafiltration method described above after having excluded likely sources of error. The possibility was considered that the T 4 contained in 350,000 cpm high specific activity 125 I]T 4 added to AF samples was reduced to approximately 70,000 cpm. AF samples from the second trimester were assayed as described for CF, because of the sudden increase in protein content and T 4 binding capacity compared with those of the first trimester AF. Figure 3 shows the total T 4 concentration, the percent FT 4 , and the FT 4 concentration in matched samples of CF and AF. The mean percent FT 4 in CF was much higher than that in MS (0.42% vs. 0.012-0.028%), and even higher (21.9%) in first trimester AF. There was a sharp decrease in the percent FT 4 (to 0.38%), between the end of the first and the beginning of the second trimester, which corresponds to the period when the fetus starts producing urine (10, 11, 14) . In both extraembryonic cavities the total T 4 concentration changed inversely to that of percent FT 4 . The resulting concentrations of FT 4 in the different compartments were buffered and much more similar to each other than the very different concentrations of total T 4 . In both compartments FT 4 correlated with T 4 (r ϭ 0.86; P Ͻ 0.001 for CF and r ϭ 0.55; P ϭ 0.014 for AF). The FT 4 concentrations of both compartments were also correlated (r ϭ 0.84; P ϭ 0.005).
The values of FT 3 obtained for CF are tentative. The mean percent FT 3 corresponding to 28 samples was 0.78 Ϯ 0.08%, higher than the percent FT 4 in the same fluid. The CF samples used for this determination were not the same ones used for the tentative determination of T 3 , and individual FT 3 concentrations could not be calculated. Using the mean percent FT 3 value and the mean tentative T 3 concentration, a value of 0.19 pmol/liter was estimated for FT 3 . This would be no more than 3% of that in first trimester MS (6.32 Ϯ 0.25 pmol/liter).
TTR was present in CF, and its concentration increased with gestational age (r ϭ 0.82; P Ͻ 0.001), with values ranging from 0.30 fmol/liter at 7 wk to about 0.56 fmol/liter between 9 -11 wk. The concentrations of ␣ 1 -, ␣ 2 -, and ␥-globulin in CF increased significantly with gestational age, from 15 to 67 mg/dl for ␣ 1 -globulin, from 8 to 45 mg/dl for ␣ 2 -globulin, and from 31 to 105 mg/dl for ␥-globulin. Changes in the concentrations of all of these proteins were gestational age dependent and independent of maternal thyroid status. Total T 4 also increased with gestational age, and a positive correlation was found between CF T 4 and TTR (r ϭ 0.62; P ϭ 0.01) and between T 4 and ␣ 1 -, ␣ 2 -, and ␥-globulin concentrations. However, only the correlation between T 4 and ␣ 1 -globulin persisted after adjusting for gestational age (r ϭ 0.74; P Ͻ 0.01).
Contrary to the increase in hCG concentrations occurring in MS during the first trimester, ranging in the present series from 16,665-175,500 IU/liter between 5 and 10 wk gestation, the hCG concentrations decreased in CF from 385,000 to 81,000 IU/liter. No correlation persisted between T 4 and hCG after correction for gestational age in either CF or MS.
Thyroid hormones in fetal serum
Individual data for T 4 , FT 4 , T 3 , TBG, and TSH in FS are shown as a function of advancing gestation in Fig. 4 . T 4 and T 3 were undetectable using commercial kits in all but a few of the samples from older fetuses. Both, however, could be measured, after extraction and purification of larger volumes of serum, using the method described for CF and AF. Mean values (Ϯse) were 6.88 Ϯ 0.72 nmol/liter for total T 4 and 0.78 Ϯ 0.18 nmol/liter for total T 3 at a mean gestational age of 14.5 Ϯ 0.3 wk. There was insufficient FS to measure the percent FT 4 by the same ultrafiltration method as that used for CF and AF, but there was sufficient FS for the determination of FT 4 using a commercial kit tested for human sera, including samples with very low TBG concentrations. The mean FT 4 concentration was 5.69 Ϯ 0.40 pmol/liter, a value not significantly different from that found for second trimester AF samples (Fig. 3) . TBG in FS was undetectable (Ͻ0.091 fmol/liter) up to 15 wk, after which the mean value for six samples was 0.12 Ϯ 0.01 fmol/liter. FT 4 in FS correlated with the T 4 concentration in the same fluid (r ϭ 0.90; P Ͻ 0.001) and T 3 with T 4 (r ϭ 0.89; P Ͻ 0.001) and FT 4 (r ϭ 0.68; P ϭ 0.017). TSH in FS ranged from 2.9 -7.2 mU/liter, with a mean value of 4.31 Ϯ 0.26 mU/liter (Fig. 4) , and did not correlate with T 4 , T 3 , or FT 4 . We had not anticipated these concentrations of TSH in the serum of the human fetus before the primary capillary plexus between the hypothalamus and the median eminence develops at 18 -20 wk. TSH in FS was higher than that in MS; no correlation was found between TSH in FS and MS. We tested the possibility that despite the high specificity of the TSH Ab described by the manufacturers of the TSH kits, the very high hCG concentrations in the FS and MS might cross-react with it, and this might result in an overestimation of the true TSH concentration. This possibility was excluded; we added up to 400,000 IU/liter of both hCG␤ and native hCG to several samples of human serum without any effect on the resulting TSH value.
Comparisons between extraembryonic fluids and fetal serum
As the T 4 and T 3 concentrations in CF and AF are referred to the volume of these fluids, we compared them with those of the corresponding volume of the fluid in the fetal circulation, namely, blood, not serum. The concentrations in blood have been calculated from those in serum by assuming a 50% hematocrit. The concentrations of T 4 or T 3 in CF, AF, and fetal blood were plotted simultaneously against gestational age. These plots showed that, with development, there was a progressive and continuous increase in total T 4 and T 3 in the embryonic and fetal fluids bathing the yolk sac and fetal tissues. The data fitted exponential functions of age, with r ϭ 0.89 for total T 4 and r ϭ 0.87 for total T 3 (P Ͻ 0.001 for both). On the contrary, as shown in Fig. 5, FT 4 concentrations in the embryonic and fetal fluids remained fairly constant.
Concentrations of iodothyronines in FS could only be compared with those in second trimester AF, because agematched CF cannot be obtained: no correlations were found between both fluids for T 4 , FT 4 , or T 3 , but this might be due to the very small number of second trimester AF samples for which all of these data were available.
Comparison of hormones in fetal fluids with maternal thyroid status
Most of the gestational age-related changes in parameters of maternal thyroid hormone status of the present study agree with those already described by others for early pregnancy (23) . Thus, TBG increased from 5 to 17 wk (r ϭ 0.65; P Ͻ 0.001). Circulating T 4 (Table 1 ) also increased with advancing gestation (r ϭ 0.34; P ϭ 0.011) and was higher in the second trimester compared with the first (P ϭ 0.001). Changes in total T 3 were similar, with second trimester values higher than those in the first trimester (P Ͻ 0.001). There was no appreciable difference in TSH between the trimesters. FT 4 was higher in the first trimester compared with the second (Table 1 ) and negatively correlated to gestational age (r ϭ Ϫ0.40; P ϭ 0.013). In the present study, however, FT 3 concentrations and FT 3 /FT 4 ratios increased from the first to the second trimester. In the first trimester, T 4 in CF was positively correlated to T 4 in MS (r ϭ 0.61; P Ͻ 0.001) and in the second trimester T 4 in FS was correlated to FT 4 in MS (r ϭ 0.57; P ϭ 0.14), but T 3 in FS was not correlated to MS T 3 or FT 3 . Neither T 4 nor FT 4 in AF correlated with these variables in MS in either the first or second trimester. Figure 5 shows individual values of T 4 and FT 4 for series C, which comprised not only samples of CF and AF, but also those of fetal and maternal blood. These concentrations were derived from the serum values, assuming a 50% hematocrit. The highest T 4 concentrations in fetal blood were at least 4 and T 3 shown were obtained after extraction, purification, and RIA, as performed for CF and AF samples, using larger volumes of serum than permitted by the kits. i.h., In-house method; c.k., commercial kit.
10-fold lower than those in maternal blood and 100-fold lower, or more, in CF and AF compared with maternal blood. In contrast, the differences between FT 4 in the fetal and maternal compartments were much smaller than those observed for total T 4 . The mean FT 4 concentration in CF (see Fig.  3 ) reached 45% of the mean maternal blood value (9.4 pmol FT 4 /liter blood, derived from 18.4 pmol FT 4 /liter serum), and 53% of the reference blood value for the general population (7.64 pmol FT 4 /liter blood, derived from 15.3 pmol/ liter serum). The mean FT 4 in AF was similar to that in maternal blood, and the mean FT 4 in fetal blood reached 43% of the maternal value (51% of that in the general euthyroid adult population).
Discussion
Total T 4 concentrations increase steadily during the first half of pregnancy in both maternal and fetal compartments. T 3 concentrations in fetal fluids are at least 10-fold lower than those of T 4 , whereas rT 3 in CF and AF is higher than that in the maternal circulation. T 4 in fetal fluids is directly related to the thyroxinemia of euthyroid mothers, whereas no correlations were found for T 3 or rT 3 between the maternal and fetal compartments. Findings are consistent with present concepts of maternal-fetal transfer of molecules (13) . During the first trimester maternal T 4 is transferred into the exocoelomic cavity and subsequently into the fetal gut and circulation via the secondary yolk sac; during the second trimester, it is transferred directly into fetal blood.
Synthesis of TTR by the yolk sac epithelium (14, 15, 25) then facilitates transfer of FT 4 from the CF into the yolk sac, and its early synthesis by choroid plexus epithelium (26) enhances the transfer of T 4 into cerebral structures. The composition of the AF is more likely to reflect fetal metabolism of the iodothyronines, although limited exchanges between the two fluid cavities occur during the first trimester (13) . The marked change in AF T 4 between the first and second trimesters is probably linked to the onset of glomerular filtration and direct excretion of fetal proteins into this cavity (10) .
The present results neither confirm nor exclude maternal T 3 transfer into first trimester CF. T 3 in the second trimester FS is not correlated to T 3 or FT 3 in MS, but to the T 4 and FT 4 concentrations in the same fetal compartment, suggesting that the T 3 and FT 3 in early fetal fluids are not transferred from the mother, but result from metabolism of the maternal T 4 that reached fetal tissues.
The low concentrations in fetal fluids of T 3 , the high concentrations of rT 3 , and the high molar rT 3 /T 4 ratios suggest that iodothyronines transferred from maternal to fetal fluids in early pregnancy undergo the same inactivating processes that are characteristic of later fetal development (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) . These are attributed to high activities of inner ring 5Ј-iodothyronine deiodinase (D-III), an inner ring deiodinating isoenzyme with preference for T 3 over T 4 as substrate, and of sulfo-transferases, producing T 4 and T 3 sulfates. High D-III activities have been described in the decidua, most placental cellular types and membranes, and many fetal tissues. Also present in placenta and some fetal tissues (i.e. brain, brown adipose tissue, and pituitary) is the 5ЈD-II isoform, which permits local intracellular generation of T 3 from T 4 . 5ЈD-I, an important source of the systemic T 3 needed for the supply of intracellular T 3 to other tissues (i.e. liver, lung, and kidney), appears much later during perinatal development.
D-III activity in uterus and placenta constitutes an important barrier for the transfer of maternal T 4 and T 3 to the fetal compartment. D-III in placental membranes and fetal tissues further inactivates the iodothyronines escaping the barrier and is responsible, together with high sulfo-transferase activities, for the low T 3 and high rT 3 levels characteristic of fetal compartments. Studies in animal models and humans show that placental 5D-III activity is not affected by maternal thyroid hormone status (29, 37) ; a decrease in the amount of substrate, namely maternal circulating T 4 and T 3 , results in lower concentrations of the hormones in fetal fluids. This conclusion is strongly supported by the positive correlations between T 4 in fetal fluids and circulating T 4 or FT 4 levels in their euthyroid mothers.
The T 4 in fetal fluids that is actually available to tissues, namely FT 4 , is much higher than expected in adults with comparably low circulating T 4 . FT 4 in fetal fluids reaches concentrations similar to those exerting biological effects in adults. Such concentrations may well be biologically relevant for the early developing brain, as T 3 -occupied nuclear receptors are already found (2, 3, 34) . Our results reconcile apparently contradictory observations, namely, that maternal thyroid hormones are needed by the early developing brain, but at the same time they are prevented from reaching the fetal compartment during a period of development when the mother is their only source. Present findings show that, if such a barrier were not effective and T 4 and T 3 in fetal and maternal fluids were the same, the FT 4 and FT 3 available to developing tissues could be excessive and potentially harmful.
The unexpected similarity of the concentrations of FT 4 in maternal and fetal fluids is related to major qualitative and quantitative differences in thyroid hormone-binding proteins. TBG in first trimester fetal fluid is not detectable, and its concentration in early FS is very low. TTR (38) and some of the T 4 -binding proteins of the ␣ 1 -globulin fraction, such as ␣ 1 -antitrypsin, ␣ 1 -antichymotrypsin, and ␣ 1 -fetoprotein (39 -41) , are present in CF at low concentrations. Thus, the proportion of maternal T 4 that reaches the fetal fluid cavities and is found in the free form, i.e. the percent FT 4 , is much higher than that in adults; the resulting FT 4 concentrations in fetal and maternal fluids become similar. The protein composition of fetal fluids is defined ontogenically and is not affected by maternal thyroid status. As the thyroid hormone-binding capacity in each fluid is far in excess of the total concentrations of iodothyronines, the FT 4 in the fetal fluid compartments is determined by their total T 4 . The latter, in turn, is correlated to circulating maternal T 4 (first trimester) or FT 4 (second trimester); a decrease in maternal T 4 or FT 4 thus results in a concordant decrease in FT 4 in fetal fluids and, consequently, in tissues.
T 4 and T 3 have been found in different tissues between 9 and 18 wk gestation (2, 3, 34) , providing direct evidence that FT 4 (and possibly FT 3 ) reaching fetal fluids actually enters tissues; the concentration of T 3 in the cortex at 13 wk gestation may actually reach 50 -60% of the values reported for adults (42) , with 20 -34% thyroid hormone nuclear receptor occupancy by T 3 (43) . These estimates are approximate and do not take into account that different tissues and organs or cell types within the same organ have specific temporal patterns of development, and their requirements for T 3 may vary widely. This would be of special importance early in life, when either a deficient or an excessive supply of hormone would result in the premature or delayed onset of biological events and an irreversible loss of opportunity for orderly development.
The ontogenetically programmed expression of 5ЈD-II and 5D-III is an important mechanism to achieve tightly controlled concentrations of T 3 in cerebral structures at different stages of development. It is frequently observed during development even in tissues other than the brain and in mammalian and nonmammalian species (34, 44, 45) , overcoming the fact that these are all exposed to the same concentrations of FT 4 or FT 3 in fetal fluids. The importance of the availability of T 4 over T 3 becomes evident, as T 4 is the initial substrate of these regulatory cascades that are determined ontogenically at cell-specific developmental stages. Relatively high T 3 levels and nuclear receptor occupancy by T 3 have indeed been found in the early human cortex (2, 3, 43) despite very low FT 3 in fetal fluids, but present results show that FT 4 is relatively normal and could provide enough substrate for generation of sufficient T 3 by 5ЈD-II deiodination. This enzyme is already present in the cortex at 11-14 wk gestational age (46) . Intracellular T 3 concentrations in other fetal tissues, such as liver, heart, and lung, however, were still undetectable at 18 wk gestation (2, 3, 43) . These tissues depend mostly on systemic T 3 generated by the 5ЈD-I, an enzyme that is only expressed much later, near term or postnatally.
In the rat, maternal T 4 is the principal source of intracellular T 3 in the early developing brain (47, 48) . Moreover, its local generation from T 4 of maternal origin protects the fetal brain from T 3 deficiency in cases of fetal thyroid failure, because cerebral 5ЈD-II activity increases markedly in response to a minor decrease in T 4 (49, 50) , compensating for the decreased availability of substrate by generating more T 3 . These findings in rat fetuses correspond to a period of brain development that occurs during the second half of human pregnancy. Whether they are operative in earlier stages of pregnancy has not been fully established. Karmarkar et al. (46) found that 5ЈD-II activity in the human cerebral cortex at 11-14 wk gestation did not respond to a decrease in maternal T 4 . This suggests that down-regulation of 5ЈD-II activity by T 4 is delayed with respect to the timing of onset of its expression. A response was detected later, at 15-18 wk, but appeared to be inadequate, because T 3 in the cortex remained low. Therefore, in the absence of a compensatory regulatory response of cerebral 5ЈD-II early in development, a decrease in maternal T 4 would ultimately result in a lower intracellular T 3 concentration.
Biological effects of thyroid hormone have not yet been identified in early human fetal brain, but recent studies show that maternal hypothyroidism early in pregnancy results in the inappropriate expression of specific genes in the fetal rat brain (51, 52) and in irreversible alterations of the migration of cells in the cortex and hippocampus (53) . The latter are also observed in the progeny from iodine-deficient rat dams (54) that are hypothyroxinemic but not hypothyroid. A very short period of goitrogen-induced mild hypothyroxinemia early in pregnancy is also sufficient to induce both abnormal migration and permanent neurological damage (i.e. increased audiogenic seizure susceptibility) (55) . Alterations of migration are easily visualized by a significant increase in heterotopic cells in the subcortical white matter. This increase has been observed in human fetuses from an iodine-deficient area (56) , suggesting that human cerebral cytoarchitecture and the establishment of normal circuits are also affected by early ma-ternal hypothyroxinemia; in humans the two main waves of migration of cells in the neocortex occur before midgestation, with peaks at 8 -10 and 12 wk gestation (57) .
In all FS samples we examined in this study TSH values were relatively high and did not correlate with maternal TSH, confirming a previous report with fewer samples (16) . Studies on sera from normal and anencephalic human fetuses have shown that TSH bioactivity is greatly increased with respect to that circulating in the mothers (58, 59), confirming that it is not of maternal origin. Some of the results suggest the existence of sources of fetal TSH that are not under hypothalamic neuroendocrine control. In the rat the brain is one of these sources (60) . A TSH receptor has been found in early human fetal brain and human astrocytes in primary culture (61) . This receptor mediates extrathyroidal cAMP-independent biological effects of TSH, among which is, interestingly, the stimulation of 5ЈD-II in astroglial cells (62) .
In summary, we here show that first trimester fetal tissues are exposed to concentrations of FT 4 in the same range as those available to adult tissues. These concentrations depend ultimately on the circulating maternal levels of T 4 or FT 4 . Even in euthyroid women, a decrease in this maternal supply results in lower concentrations of FT 4 in fetal fluids and, consequently, of T 4 available to the developing brain. We here propose that this T 4 would determine the amount of T 3 , generated locally by 5ЈD-II deiodination, that ultimately binds to thyroid hormone nuclear receptors in different brain structures and triggers biological responses early in gestation in orderly sequence. Ensuring maternal T 4 levels appropriate for the stage of pregnancy, regardless of whether TSH is increased or whether overt or subclinical hypothyroidism is detected, may decrease the risk of neurodevelopmental defects in the child (5) . A major cause of maternal hypothyroxinemia worldwide is an inadequate iodine intake, which is easily avoided by encouraging pregnant women to take iodine supplements from early pregnancy even in countries such as the U.S. (1) .
